FDA Puts REMS Requirements on Hold to Ensure Continuity of C

The FDA will temporarily not enforce certain clozapine REMS program requirements to ensure continuity of care for patients taking the antipsychotic.

Related Keywords

, Drug Administration , Medscape Medical News , Schizophrenia , Psychosis , Mental Illness , Mental Disorder , Sychiatric Disorder , Sychiatric Illness , Antipsychotics , Neuroleptics , Neuroleptic Drugs , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Risk Evaluation And Mitigation Strategies Rems , Adverse Effects , Side Effects , Neutropenia , Neutrophils , Death And Dying ,